We are pleased to have ranked first and improved our score in the Access to Medicine Index. We welcome the recognition for having the largest proportion of our R&D pipeline dedicated to priority diseases and for the creation of an integrated Global Health R&D unit to stimulate collaboration.

Improving the health of people in developing countries is a shared responsibility and we also welcome the achievements of other companies highlighted by the Index. We need a much stronger focus on collaboration both within our industry and across sectors, and we look forward to working with ATMi on addressing that. Further progress must be measured by the collective impact of business and other stakeholders working together, in addition to the performance of individual companies alone.

GSK - a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For more information, visit about us.

Attachments

  • Original document
  • Permalink

Disclaimer

GSK - GlaxoSmithKline plc published this content on 20 November 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 20 November 2018 13:30:01 UTC